The accuracy of ultrasensitive PSA in predicting disease progression after radical prostatectomy

Fuente: Wiley Open Access
Saved in:
Bibliographic Details
Main Authors: Heikki Seikkula, Jaakko Hyysalo, Mikael Högerman, Peter J. Boström, Otto Ettala
Format: Artículo Open Access
Published: Wiley 2024
Subjects:
Online Access:
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1867005565135224833
author Heikki Seikkula
Jaakko Hyysalo
Mikael Högerman
Peter J. Boström
Otto Ettala
author_facet Heikki Seikkula
Jaakko Hyysalo
Mikael Högerman
Peter J. Boström
Otto Ettala
Heikki Seikkula
Jaakko Hyysalo
Mikael Högerman
Peter J. Boström
Otto Ettala
collection Wiley Open Access
contents The accuracy of ultrasensitive PSA in predicting disease progression after radical prostatectomy Heikki Seikkula Jaakko Hyysalo Mikael Högerman Peter J. Boström Otto Ettala BJUI Compass AbstractObjectivesTo assess the role of ultrasensitive PSA values (usPSA) after radical prostatectomy in predicting the subsequent biochemical recurrence (BCR).Material and methodsThe study included 1836 patients who underwent open or robot‐assisted RP at Turku University Hospital between 2003 and 2018. Exclusion criteria involved patients with adjuvant treatments and those who did not reach a PSA nadir <0.1 ng/ml, resulting in a final cohort of 1313 patients. The prognostic impact of the optimal usPSA nadir cut‐off value 6 months after RP was investigated to predict subsequent BCR for the whole cohort (N = 1313). The optimal usPSA cut‐off value was determined for patients at 3–5 years post‐surgery (N = 806) and beyond 5 years (N = 493) of follow‐up. We used the area under the curve (AUC) calculation and the Kaplan–Meier method.ResultsIn a cohort with a median age of 64, primarily featuring Gleason score 7 prostate cancer. uPSA nadir of 0.01 ng/ml (AUC = 0.80) at the first monitoring post‐surgery emerged as the optimal cut‐off for identifying subjects at low (80%) or high (20%) risk of BCR within the first 3 years. Beyond this period, uPSA values during the first 3 [(AUC = 0.89; 3–5 years post‐surgery) and (AUC = 0.81; beyond 5 years)] and 5 post‐surgery years (AUC = 0.85) outperformed uPSA nadir in predicting subsequent BCR. Notably, EAU‐defined high‐risk patients with low uPSA nadir maintained substantial BCR‐free survival.ConclusionIn conclusion, a low usPSA predicts minimal BCR risk over the next 2–3 years post‐measurement. Patients with low usPSA can benefit from reduced post‐surgery PSA monitoring at 2‐ to 3‐year intervals without compromising outcomes. This strategic approach optimizes resource allocation in busy urological outpatient clinics, especially valuable in publicly reimbursed healthcare systems like Finland. 10.1002/bco2.413 http://creativecommons.org/licenses/by/4.0/
doi_str_mv 10.1002/bco2.413
format Artículo Open Access
id wiley_oa_10_1002_bco2_413
institution Wiley Open Access
license_str_mv http://creativecommons.org/licenses/by/4.0/
publishDate 2024
publisher Wiley
record_format wiley_oa
spellingShingle The accuracy of ultrasensitive PSA in predicting disease progression after radical prostatectomy
Heikki Seikkula
Jaakko Hyysalo
Mikael Högerman
Peter J. Boström
Otto Ettala
BJUI Compass
The accuracy of ultrasensitive PSA in predicting disease progression after radical prostatectomy Heikki Seikkula Jaakko Hyysalo Mikael Högerman Peter J. Boström Otto Ettala BJUI Compass AbstractObjectivesTo assess the role of ultrasensitive PSA values (usPSA) after radical prostatectomy in predicting the subsequent biochemical recurrence (BCR).Material and methodsThe study included 1836 patients who underwent open or robot‐assisted RP at Turku University Hospital between 2003 and 2018. Exclusion criteria involved patients with adjuvant treatments and those who did not reach a PSA nadir <0.1 ng/ml, resulting in a final cohort of 1313 patients. The prognostic impact of the optimal usPSA nadir cut‐off value 6 months after RP was investigated to predict subsequent BCR for the whole cohort (N = 1313). The optimal usPSA cut‐off value was determined for patients at 3–5 years post‐surgery (N = 806) and beyond 5 years (N = 493) of follow‐up. We used the area under the curve (AUC) calculation and the Kaplan–Meier method.ResultsIn a cohort with a median age of 64, primarily featuring Gleason score 7 prostate cancer. uPSA nadir of 0.01 ng/ml (AUC = 0.80) at the first monitoring post‐surgery emerged as the optimal cut‐off for identifying subjects at low (80%) or high (20%) risk of BCR within the first 3 years. Beyond this period, uPSA values during the first 3 [(AUC = 0.89; 3–5 years post‐surgery) and (AUC = 0.81; beyond 5 years)] and 5 post‐surgery years (AUC = 0.85) outperformed uPSA nadir in predicting subsequent BCR. Notably, EAU‐defined high‐risk patients with low uPSA nadir maintained substantial BCR‐free survival.ConclusionIn conclusion, a low usPSA predicts minimal BCR risk over the next 2–3 years post‐measurement. Patients with low usPSA can benefit from reduced post‐surgery PSA monitoring at 2‐ to 3‐year intervals without compromising outcomes. This strategic approach optimizes resource allocation in busy urological outpatient clinics, especially valuable in publicly reimbursed healthcare systems like Finland. 10.1002/bco2.413 http://creativecommons.org/licenses/by/4.0/
title The accuracy of ultrasensitive PSA in predicting disease progression after radical prostatectomy
topic BJUI Compass
url https://bjui-journals.onlinelibrary.wiley.com/doi/10.1002/bco2.413